Drug Profile
Research programme: antibacterials - AstraZeneca/CrystalGenomics
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator AstraZeneca; CrystalGenomics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections